A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
Sponsor: Aclaris Therapeutics, Inc.
This PHASE2 trial investigates Common Wart and is currently completed. Aclaris Therapeutics, Inc. leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2019 — May 2019 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aclaris Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .